AstraZeneca PLC (AZN) — Analysis Summary
AstraZeneca PLC (AZN) has a market cap of $254.01B with year-over-year revenue growth of +8.6%. Net margin stands at 17.4%. The stock trades at a P/E ratio of 24.8.
Key Takeaways
- Revenue changed +8.6% year-over-year
- Net margin of 17.4%
- P/E ratio of 24.8
Compared with its sector, AZN posted revenue growth of +8.6% and trades at a P/E of 24.8.
AstraZeneca PLC (AZN)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Current ratio at 0.94x — current liabilities exceed current assets
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
Employees
96,100
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$1.59
Dividend Yield
0.97%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.